Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accounts Payables (2016 - 2026)

Anika Therapeutics has reported Accounts Payables over the past 17 years, most recently at $6.3 million for Q1 2026.

  • Quarterly Accounts Payables rose 20.13% to $6.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Mar 2026, up 20.13% year-over-year, with the annual reading at $6.0 million for FY2025, 7.55% up from the prior year.
  • Accounts Payables was $6.3 million for Q1 2026 at Anika Therapeutics, up from $6.0 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $10.0 million in Q1 2024 and troughed at $4.7 million in Q3 2025.
  • The 5-year median for Accounts Payables is $7.4 million (2022), against an average of $7.3 million.
  • Year-over-year, Accounts Payables rose 25.81% in 2024 and then tumbled 52.26% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $9.1 million in 2022, then crashed by 31.74% to $6.2 million in 2023, then dropped by 9.32% to $5.6 million in 2024, then rose by 7.55% to $6.0 million in 2025, then increased by 4.93% to $6.3 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Accounts Payables are $6.3 million (Q1 2026), $6.0 million (Q4 2025), and $4.7 million (Q3 2025).